HALOZYME REPORTS SECOND QUARTER 2022 FINANCIAL AND OPERATING RESULTS

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to HALOZYME REPORTS SECOND QUARTER 2022 FINANCIAL AND OPERATING RESULTS

Halozyme Therapeutics (HALO) Tops Q2 EPS by 6c, Offers Guidance

August 9, 2022 5:04 PM EDT

Halozyme Therapeutics (NASDAQ: HALO) reported Q2 EPS of $0.53, $0.06 better than the analyst estimate of $0.47. Revenue for the quarter came in at $152.4 million versus the consensus estimate of $138.63 million.

GUIDANCE:

Halozyme Therapeutics sees FY2022 EPS of $2.10-$2.25, versus the consensus of $2.23.... More